Skip to Content
MilliporeSigma
All Photos(2)

Documents

GF58573648

Lutetium

powder, 1g, max. particle size 500 micron, 99.9%

Synonym(s):

Lutetium, LU006010

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
Lu
CAS Number:
7439-94-3
Molecular Weight:
174.97
MDL number:
MFCD00011098
UNSPSC Code:
11101711
PubChem Substance ID:
329808836
NACRES:
NA.23

Assay

99.9%

form

powder

manufacturer/tradename

Goodfellow 585-736-48

resistivity

54 μΩ-cm, 20°C

particle size

500 μm

bp

3402 °C (lit.)

mp

1663 °C (lit.)

density

9.84 g/mL at 25 °C (lit.)

SMILES string

[Lu]

InChI

1S/Lu

InChI key

OHSVLFRHMCKCQY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Pictograms

Flame
GHS02

Signal Word

Danger

Hazard Statements

H228

Hazard Classifications

Flam. Sol. 1

Storage Class Code

4.1B - Flammable solid hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R O Perez et al.
Techniques in coloproctology, 18(8), 699-708 (2014-02-11)
Molecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant
S Panigone et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 50(4), 310-321 (2006-10-18)
Optimization of therapy for individual patients remains a goal of clinical practice. Radionuclide imaging can identify those patients who may benefit from subsequent targeted therapy by providing regional information on the distribution of the target. An ideal situation may be
B L R Kam et al.
European journal of nuclear medicine and molecular imaging, 39 Suppl 1, S103-S112 (2012-03-06)
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The
Alin Chirindel et al.
AJR. American journal of roentgenology, 204(5), 1093-1099 (2015-04-24)
The purpose of this study is to evaluate the performance of PET-derived parameters as prognostic markers for overall survival (OS) and progression-free survival (PFS) outcome in patients with pancreatic adenocarcinoma. We conducted a retrospective study of 106 patients (62 men
Vijay Kumar Ichpujani et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(11), 2319-2332 (2014-12-02)
The fusion imaging modality of positron-emission tomography-computed tomography (PET-CT) has emerged as an important modality in the management of recurrent head and neck tumors. The aims of this study were to assess the role of PET-CT in the detection of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service